Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its stake in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 74.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 52,189 shares of the biotechnology company’s stock after selling 153,567 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.19% of Arcturus Therapeutics worth $886,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Empire Life Investments Inc. lifted its holdings in Arcturus Therapeutics by 85.5% during the fourth quarter. Empire Life Investments Inc. now owns 279,463 shares of the biotechnology company’s stock valued at $4,742,000 after purchasing an additional 128,771 shares in the last quarter. Deutsche Bank AG lifted its holdings in Arcturus Therapeutics by 42.7% during the fourth quarter. Deutsche Bank AG now owns 24,768 shares of the biotechnology company’s stock valued at $420,000 after purchasing an additional 7,417 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Arcturus Therapeutics by 6.8% during the fourth quarter. Vanguard Group Inc. now owns 1,684,561 shares of the biotechnology company’s stock valued at $28,587,000 after purchasing an additional 107,635 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in Arcturus Therapeutics by 52.7% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 13,461 shares of the biotechnology company’s stock valued at $241,000 after purchasing an additional 4,647 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Arcturus Therapeutics by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 554,984 shares of the biotechnology company’s stock valued at $9,421,000 after purchasing an additional 3,186 shares in the last quarter. 94.54% of the stock is owned by hedge funds and other institutional investors.

Arcturus Therapeutics Trading Up 2.9%

NASDAQ:ARCT opened at $12.90 on Wednesday. The company’s 50-day moving average price is $11.55 and its 200-day moving average price is $14.53. Arcturus Therapeutics Holdings Inc. has a twelve month low of $8.04 and a twelve month high of $34.17. The company has a market cap of $349.86 million, a P/E ratio of -5.81 and a beta of 2.30.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its earnings results on Monday, May 12th. The biotechnology company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($1.58) by $1.06. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. The company had revenue of $29.38 million for the quarter, compared to the consensus estimate of $25.64 million. On average, analysts expect that Arcturus Therapeutics Holdings Inc. will post -2.22 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. Wells Fargo & Company decreased their price objective on shares of Arcturus Therapeutics from $50.00 to $45.00 and set an “overweight” rating on the stock in a report on Wednesday, May 14th. Canaccord Genuity Group decreased their price target on shares of Arcturus Therapeutics from $68.00 to $66.00 and set a “buy” rating on the stock in a research note on Tuesday, May 13th. HC Wainwright reissued a “buy” rating and issued a $60.00 price target on shares of Arcturus Therapeutics in a research note on Thursday, April 10th. Wall Street Zen raised shares of Arcturus Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, May 22nd. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Arcturus Therapeutics in a research note on Friday, March 7th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $53.50.

Arcturus Therapeutics Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.